The Status of Serotonin-Selective Pharmacotherapy in the Treatment of Alcohol Dependence

  • Helen M. Pettinati
  • Henry R. Kranzler
  • Julie Madaras
Chapter
Part of the Recent Developments in Alcoholism book series (RDIA, volume 16)

Abstract

Research performed during the past 20 years has shown that serotonin (5-hydroxytrypt-amine; 5-HT) neurotransmission is related to alcohol dependence. Both theoretical and empirical research have supported the idea that alcohol dependence is a chronic disease and that, in addition, biological vulnerabilities contribute to the pathogenesis of alcohol dependence. Preclinical studies have consistently demonstrated that there is a relationship between 5-HT function and alcohol consumption. Furthermore, there is evidence building that lends support for the existence of distinct alcoholic subtypes that may be differentiated by the type or complexity of their 5-HT dysfunction. Beyond excessive drinking, behaviors that are indicators of 5-HT dysregulation are depression, anxiety, impulsiveness, and early-onset problem drinking. This chapter will discuss the usefulness of 5-HT-selective pharmacotherapy in treating alcohol dependence and will provide both historical and current perspectives on its use.

Keywords

Alcohol Dependence Ethanol Intake Excessive Drinking Reduce Alcohol Consumption Drinking Outcome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anthenelli, R.M., & Maxwell, R.A. (2000). Cigarette smoking decreases the prolactin response to serotonergic stimulation in subgroups of alcoholics and controls. Alcoholism: Clinical and Experimental Research 24, 987–995.Google Scholar
  2. Åsberg, M., Schalling, D., & Träskman-Bendz, L. (1987). Psychobiology of suicide, impulsivity, and related phenomena. In H.Y. Meltzer (ed.), Psychopharmacology: The Third Generation of Progress. New York: Raven Press, pp. 665–668.Google Scholar
  3. Babor, T.F., Dolinsky, Z., Rounsaville, B., & Jaffe, J. (1988). Unitary versus multidimensional models of alcoholism treatment outcome: An empirical study. Journal of Studies on Alcohol 49, 167–177.PubMedGoogle Scholar
  4. Babor, T.F., Dolinsky, Z., Meyer, R.E., Hesselbrock, M., Hofmann, M., & Tennen, H. (1992a). Types of alcoholics: Concurrent and predictive validity of some common classification schemes. British Journal of Addiction 87, 1415–1431.PubMedGoogle Scholar
  5. Babor, T.F., Hofmann, M., Del Boca, F.K., Hesselbrock, V., Meyer, R.E., Dolinsky, Z.S., & Rounsaville, B. (1992b). Types of alcoholics, 1: Evidence for an empirically derived typology based on indicators of vulnerability and severity. Archives of General Psychiatry 49, 599–608.PubMedGoogle Scholar
  6. Ballenger, J., Goodwin, F., Major, L., & Brown, G. (1979). Alcohol and central serotonin metabolism in man. Archives of General Psychiatry 36, 224–227.PubMedGoogle Scholar
  7. Balldin, J., Berggren, U., Engel, J., Eriksson, M., Hard, E., & Soderpalm, B. (1994). Effect of citalopram on alcohol intake in heavy drinkers. Alcoholism: Clinical and Experimental Research 18, 1133–1136.Google Scholar
  8. Banki, C. (1981). Factors influencing monoamine metabolites and tryptophan in patients with alcohol dependence. Journal of Neural Transmission 50, 89–101.PubMedCrossRefGoogle Scholar
  9. Brown, G.L., Goodwin, F.K., Ballenger, J.C., Goyer, P.F., & Major, L.F. (1979). Aggression in humans correlates with cerebrospinal fluid amine metabolites. Psychiatry Research 1, 131–139.PubMedCrossRefGoogle Scholar
  10. Buydens-Branchey, L., Branchey, M.H., & Noumair, D. (1989). Age of alcoholism onset. I. Relationship to psychopathology. Archives of General Psychiatry 46, 225–230.PubMedGoogle Scholar
  11. Buydens-Branchey, L., Branchey, M.H., Noumair, D., & Lieber, C.S. (1989). Age of alcoholism onset. II. Relationship to susceptibility to serotonin precursor availability. Archives of General Psychiatry 46, 231–236.PubMedGoogle Scholar
  12. Carmichael, F., & Israel, Y. (1975). Effects of ethanol on neurotransmitter release by rat brain cortical slices. Journal of Pharmacology and Experimental Therapeutics 193, 824–834.PubMedGoogle Scholar
  13. Cloninger, C.R. (1987). Neurogenetic adaptive mechanisms in alcoholism. Science 236, 410–416.PubMedGoogle Scholar
  14. Coccaro, E.F., & Murphy, D.L. (eds.). (1990). Serotonin in Major Psychiatric Disorders. Washington, DC: American Psychiatric Press.Google Scholar
  15. Coccaro, E.F., Siever, L., Klar, H.M., Maurer, G., Cochrane, K., Cooper, T.B., Mohs, R.C., & Davis, K.L. (1989). Serotonergic studies in patients with affective and personality disorders: Correlates with suicidal and impulsive aggressive behavior. Archives of General Psychiatry 46, 587–599.PubMedGoogle Scholar
  16. Collins, D.M., & Myers, R.D. (1987). Buspirone attenuates volitional alcohol intake in the chronically drinking monkey. Alcohol and Alcoholism 4, 49–56.Google Scholar
  17. Cornelius, J.R., Salloum, I.M., Ehler, J.G., Jarrett, P.J., Cornelius, M.D., Perel, J.M., Thase, M.E., & Black, A. (1997). Fluoxetine in depressed alcoholics: A double-blind, placebo-controlled trial. Archives of General Psychiatry 54, 700–705.PubMedGoogle Scholar
  18. Eison, A.S., & Temple, D.L. (1986). Buspirone: Review of its pharmacology and current perspectives on its mechanism of action. American Journal of Medicine 80 (3B), 1–9.PubMedGoogle Scholar
  19. Engel, J.A., Fahlke, C., Hard, E., Johannessen, K., Svensson, L., & Soderpalm, P. (1992). Serotonergic and dopaminergic involvement in ethanol intake. Clinical Neuropharmacology 15(Suppl 1), 64A–65A.PubMedGoogle Scholar
  20. Farren, C.K., Ziedonis, D., Clare, A.W., Hammeedi, F.A., & Dinan, T.G. (1995). D-fenfluramine-induced prolactin responses in postwithdrawal alcoholics and controls. Alcoholism: Clinical and Experimental Research 19, 1578–1582.Google Scholar
  21. Fils-Aime, M.L., Eckardt, M.J., George, D.T., Brown, G.L., Mefford, I., & Linnoila, M. (1996). Early-onset alcoholics have lower cerebral spinal fluid 5-hydroxyindoleacetic acid levels than late-onset alcoholics. Archives of General Psychiatry 53, 211–216.PubMedGoogle Scholar
  22. Gallant, D. (1993). Amethysic agents and adjunct behavioral therapy and psychotherapy. Alcoholism: Clinical and Experimental Research 17, 197–198.Google Scholar
  23. Gallant, D. (1999). Alcohol. In M. Galanter & H. Kleber (eds.), The American Psychiatric Press Textbook of Substance Abuse Treatment, 2nd ed. Washington: American Psychiatric Press, pp. 151–164.Google Scholar
  24. George, D.T., Benkelfat, C., Rawlings, R.R., Eckardt, M.J., Phillips, M.J., Nutt, D.J., Wynne, D., Murphy, D.L., & Linnoila, M. (1997). Behavioral and neuroendocrine responses to m-chlorophenylpiperazine in subtypes of alcoholics and in healthy comparison subjects. American Journal of Psychiatry 154, 81–87.PubMedGoogle Scholar
  25. Gorelick, D.A. (1989). Serotonin reuptake blockers and the treatment of alcoholism. In M. Galanter (ed.), Recent Developments in Alcoholism: Vol. 7. Treatment Research. New York: Plenum Press, pp. 267–281.Google Scholar
  26. Gorelick, D.A., & Paredes, A. (1992). Effect of fluoxetine on alcohol consumption in male alcoholics. Alcoholism: Clinicaland Experimental Research 16, 261–265.Google Scholar
  27. Grant, B., & Hartford, T. (1995). Comorbidity between DSM-IV alcohol use disorders and major depression: Results of a national survey. Drug and Alcohol Dependence 39, 197–206.PubMedGoogle Scholar
  28. Heinz, A., Mann, K., Weinberger, D.R., & Goldman, D. (2001). Serotonergic dysfunction, negative mood states, and response to alcohol. Alcoholism: Clinical and Experimental Research 25, 487–495.Google Scholar
  29. Higley, J., Hasert, M., Suomi, S., & Linnoila, M. (1998). The serotonin reuptake inhibitor sertraline reduces excessive alcohol consumption in nonhuman primates: Effect of stress. Neuropsychopharmacology 18, 431–443.PubMedGoogle Scholar
  30. Imperato, A., & DiChiara, G. (1986). Preferential stimulation of dopamine release in the nucleus accumbens of freely moving rats by ethanol. Journal of Pharmacology and Experimental Therapeutics 239, 219–228.PubMedGoogle Scholar
  31. Johnson, B.A. (2000). Serotonergic agents and alcoholism treatment: Rebirth of the subtype concept—a hypothesis. Alcoholism: Clinical and Experimental Research 24, 1597–1601.Google Scholar
  32. Johnson, B.A., Roache, J.D., Javors, M.A., DiClemente, C.C., Cloninger, C.R., Prihoda, T.J., Bordnick, P.S., Ait-Daoud, N., & Hensler, J. (2000). Odansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial. Journal of the American Medical Association 284(9), 963–971.PubMedGoogle Scholar
  33. Kabel, D., & Petty, F. (1996). Adouble-blind study of fluoxetine in severe alcohol dependence: Adjunctive therapy during and after inpatient treatment. Alcoholism: Clinical and Experimental Research 20, 780–784.Google Scholar
  34. Kessler, R.C., Nelson, C.B., McGonagle, K.A., Edlund, M.J., Frank, R.G., & Leaf, P.J. (1996). The epidemiology of co-occurring addictive and mental disorders: Implications for prevention and service utilization. American Journal of Orthopsychiatry 66, 17–31.PubMedGoogle Scholar
  35. Knapp, D.J., & Pohorecky, L.A. (1992). Zacopride, a 5-HT3 receptor antagonist, reduces voluntary ethanol consumption in rats. Pharmacology, Biochemistry and Behavior 41, 847–850.CrossRefGoogle Scholar
  36. Koob, G., & Roberts, A. (1999). Brain reward circuits in alcoholism. CNS Spectrums 4, 23–37.Google Scholar
  37. Koob, G., & Weiss, F. (1992). Neuropharmacology of cocaine andethanol dependence. Recent Developments in Alcoholism 10, 201–233.PubMedGoogle Scholar
  38. Kranzler, H.R. (2000). Pharmacotherapy of alcoholism: Gaps in knowledge and opportunities for research. Alcohol and Alcoholism 35, 537–547.PubMedCrossRefGoogle Scholar
  39. Kranzler, H.R., & Anton R.F. (1994). Implications of recent neuropsychopharmacologic research for understanding the etiology and development of alcoholism. Journal of Consulting and Clinical Psychology 62, 1116–1126.PubMedCrossRefGoogle Scholar
  40. Kranzler, H.R., Burleson, J.A., Del Boca, F.K., Babor, T.F., Korner, P., Brown, J., & Bohn, M.J. (1994). Buspirone treatment of anxious alcoholics: A placebo-controlled trial. Archives of General Psychiatry 51(9), 720–731.PubMedGoogle Scholar
  41. Kranzler, H.R., Burleson, J.A., Korner, P., Del Boca, F.K., Bohn, M.J., Brown, J., & Liebowitz, N. (1995). Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. American Journal of Psychiatry 152(3), 391–397.PubMedGoogle Scholar
  42. Kranzler, H.R., Burleson, J.A., Brown, J., & Babor, T.F. (1996). Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics. Alcoholism: Clinical and Experimental Research 20, 1534–1541.Google Scholar
  43. Krystal, J.H., Webb, E., Cooney, N.L., Kranzler, H.R., & Charney, D.S. (1994). Specificity of ethanol-like effects elicited by Serotonergic and noradrenergic mechanisms. Archives of General Psychiatry 51, 898–911.PubMedGoogle Scholar
  44. Lee, M.A., & Meltzer, H.Y. (1991). Neuroendocrine responses to Serotonergic agents in alcoholics. Biological Psychiatry 30, 1017–1030.PubMedCrossRefGoogle Scholar
  45. Lejoyeux, M. (1996). Use of serotonin (5-hydroxytryptamine) reuptake inhibitors in the treatment of alcoholism. Alcohol and Alcoholism 1, 69–75.Google Scholar
  46. Linnoila, M., Virkkunen, M., Scheinin, M., Nuutila, A., Rimon, R., & Goodwin, F.K. (1983). Low cerebrospinal fluid 5-Hydroxyindoleacetic acid concentration differentiates impulsive from nonimpulsive violent behavior. Life Sciences 33, 2609–2614.PubMedCrossRefGoogle Scholar
  47. Lovinger, D. (1991). Ethanolpotentiation of 5-HT3 receptor-mediated ion current in NCB-20 neuroblastoma cells. Neuroscience Letters 122, 57–60.PubMedCrossRefGoogle Scholar
  48. Maes, M., & Meltzer, H. (1995). The serotonin hypothesis of major depression. In A.C. Bloom & D.J. Kupfer (eds.), Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press, pp. 933–944.Google Scholar
  49. Malcolm, R., Anton, R.F., Randall, D.L., Johnston, A., Brady, K., & Thevos, A. (1992). A placebo-controlled trial of buspirone in anxious inpatient alcoholics. Alcoholism: Clinical and Experimental Research 16, 1007–1013.Google Scholar
  50. Marlatt, G.A. (1985). Relapse prevention: Theoretical rationale and overview of the model. In G.A. Marlatt & J.R. Gordon (eds.), Relapse Prevention. New York: Guilford, pp. 3–70.Google Scholar
  51. McGrath, P. Fluoxetine for the treatment of alcoholism and depression. In R. Litten (Chair), Does 5-HT pharmacotherapy have a role in alcohol treatment? Symposium conducted at the Annual Meeting of the Research Society on Alcoholism, Hilton Head, SC, June 1998.Google Scholar
  52. McLellan, A.T., Lewis, D.C., O’Brien, C.P., & Kleber, H.D. (2000). Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation. Journal of the American Medical Association 284(13), 1689–1695.PubMedCrossRefGoogle Scholar
  53. Mereau, G., Fadda, F., & Gessa, G. (1984). Ethanol stimulates the firing rate of nigral dopaminergic neurons in unanesthetized rats. Brain Research 292, 63–69.Google Scholar
  54. Moak, D.H., Voronin, K.E., Latham, P.K., & Anton, R.F. (2001). A double-blind placebo-controlled treatment study of sertraline in depressed alcoholics: Preliminary analysis. Alcoholism: Clinical and Experimental Research 25, 94A.Google Scholar
  55. Moeller, F.G., Dougherty, D.M., Swann A.C., Collins, D., Davis, C.M., & Cherek, D.R. (1996). Tryptophan depletion and aggressive responding in healthy males. Psychopharmacology 126, 97–103.PubMedCrossRefGoogle Scholar
  56. Myers, R., & Melchior, C.L. (1977). Alcohol and alcoholism: Role of serotonin. In W.B. Essman (ed.), Serotonin in Health and Disease: Vol. 2. Physiological Regulation and Pharmacological Action. New York: Spectrum, pp. 373–430.Google Scholar
  57. Naranjo, C.A., & Knoke, D.M. (2001). The role of selective serotonin reuptake inhibitors in reducing alcohol consumption. Journal of Clinical Psychiatry 62(Suppl 20), 18–25.PubMedGoogle Scholar
  58. Naranjo, C.A., Sellers, E.M., Roach, C.A., Woodley, D.V., Sanchez-Craig, M., & Sykora, K. (1984). Zimelidine-induced variations in alcohol intake by nondepressed heavy drinkers. Clinical Pharmacology & Therapeutics 35, 374–381.CrossRefGoogle Scholar
  59. Naranjo, C.A., Sellers, E.M., & Lawrin, M. (1986). Modulation of ethanol intake by serotonin uptake inhibitors. Journal of Clinical Psychiatry 47(Suppl 4), 16–22.PubMedGoogle Scholar
  60. Naranjo, C.A., Sellers, E.M., Sullivan, J.T., Woodley, D.V., Kadlec, K., & Sykora, K. (1987). The serotonin uptake inhibitor citalopram attenuates ethanol intake. Clinical Pharmacology & Therapeutics 41, 266–274.CrossRefGoogle Scholar
  61. Naranjo, C.A., Sullivan, J.T., Kadlec, K.E., Woodley-Remus, D.V., Kennedy, G., & Sellers, E.M. (1989). Differential effects of viqualine on alcohol intake and other consummatory behaviors. Clinical Pharmacology & Therapeutics 46, 301–309.CrossRefGoogle Scholar
  62. Naranjo, C.A., Kadlec, K.E., Sanhueza, P., Woodley-Remus, D., & Sellers, E.M. (1990). Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers. Clinical Pharmacology & Therapeutics 47, 490–498.CrossRefGoogle Scholar
  63. Pandey, S., Lumeng, L., & Li, T. (1996). 5HT-2C receptors and 5HT-2C receptor-mediated phosphoinositide hydrolysis in the brain of alcohol-preferring and alcohol-non-preferring rats. Alcoholism: Clinical and Experimental Research 20, 1038–1042.Google Scholar
  64. Pettinati, H.M. (1996). Use of serotonin selective pharmacotherapy in the treatment of alcohol dependence. Alcoholism: Clinical and Experimental Research 20(7, Suppl), 23A–29A.Google Scholar
  65. Pettinati, H.M. (2001). The use of selective serotonin reuptake inhibitors in treating alcoholic subtypes. Journal of Clinical Psychiatry 62(Suppl 20), 26–31.PubMedGoogle Scholar
  66. Pettinati, H.M., Oslin, D., & Decker, K. (2000a). Role of serotonin and serotonin-selective pharmacotherapy in alcohol dependence. CNS Spectrums 5(2), 33–46.PubMedGoogle Scholar
  67. Pettinati, H.M., Rukstalis, M.R., Luck, G.J., Volpicelli, J.R., & O’Brien, C.P. (2000b). Gender and psychiatric comorbidity: Impact on clinical presentation of alcohol dependence. American Journal on Addictions 9, 242–252.PubMedGoogle Scholar
  68. Pettinati, H.M., Volpicelli, J.R., Kranzler, H.R., Luck, G., Rukstalis, M.R., & Cnaan, A. (2000c). Sertraline treatment for alcohol dependence: Interactive effects of medication and subtype. Alcoholism: Clinical and Experimental Research 24(7), 1041–1049.Google Scholar
  69. Pettinati, H.M., Volpicelli, J.R., Luck, G., Kranzler, H.R., Rukstalis, M.R., & Cnaan, A. (2001). Double-blind clinical trial of sertraline treatment for alcohol dependence. Journal of Clinical Psychopharmacology 21(2), 143–153.PubMedCrossRefGoogle Scholar
  70. Pietraszek, M.H., Urano, T., Sumioshi, K., Serizawa, K., Takahashi, S., Takada, Y., & Takada, A. (1991). Alcohol-induced depression: Involvement of serotonin. Alcohol and Alcoholism 26(2), 155–159.PubMedGoogle Scholar
  71. Privette, T.H., Hornsby, R.I., & Myers, R.D. (1988). Buspirone alters alcohol drinking induced in rats by tetrahydropapaveroline injected into brain monoaminergic pathways. Alcohol 5, 147–152.PubMedCrossRefGoogle Scholar
  72. Regier, D.A., Farmer, M.E., Rae, D.S., Locke, B.Z., Keith, S.J., Judd, L.L., & Goodwin, F.K. (1990). Comorbidity of mental disorders with alcohol and other drug abuse: Results from the Epidemiologic Catchment Area (ECA) study. Journal of the American Medical Association 264, 2511–2518.PubMedCrossRefGoogle Scholar
  73. Roberts, A.J., McArthur, R.A., Hull, E.E., Post, C., & Koob, G.F. (1998). Effects of amperozide, 8-OH-DPAT, and FG5974 on operant responding for ethanol. Psychopharmacology 137, 25–32.PubMedCrossRefGoogle Scholar
  74. Roy, A. (1998). Placebo-controlled study of sertraline in depressed recently abstinent alcoholics. Biological Psychiatry 44, 633–637.PubMedGoogle Scholar
  75. Roy, A., & Linnoila, M. (1989). CSF studies on alcoholism and related behaviors. Progress In Neuro-Psychopharmacology & Biological Psychiatry 13, 505–511.Google Scholar
  76. Roy, A., Virkkunen, M., & Linnoila, M. (1990). Serotonin in suicide, violence, and alcoholism. In E.F. Coccaro & D.L. Murphy (eds.), Serotonin in Major Psychiatric Disorders. Washington, DC: American Pyschiatric Press, pp. 187–208.Google Scholar
  77. Sellers, E., Toneatto, T., Romach, M., Somer, G., Sobell, L., & Sobell, M. (1994). Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcoholism: Clinical and Experimental Research 18, 879–885.Google Scholar
  78. Svensson, L., Fahlke, C., Hard, E., & Engel, J.A. (1993). Involvement of the serotonergic system in ethanol intake in the rat. Alcohol 10, 219–224.PubMedCrossRefGoogle Scholar
  79. Swift, R., Davidson, D., Whelihan, W., & Kuznetsov, O. (1996). Ondansetron alters human alcohol intoxication. Biological Psychiatry 40, 514–521.PubMedCrossRefGoogle Scholar
  80. Tiihonen, J., Ryynanen, O.P., Kauhanen, J., Hakola, H.P.A., & Salaspuro, M. (1996). Citalopram in the treatment of alcoholism: A double-blind placebo-controlled study. Pharmacopsychiatry 29, 27–29.PubMedCrossRefGoogle Scholar
  81. Tollefson, G.D., Montague-Clouse, J., & Tollefson, S.L. (1992). Treatment of comorbid generalized anxiety in a recently detoxified alcoholic population with a selective serotonergic drug (buspirone). Journal of Clinical Psychopharmacology 12, 19–26.PubMedGoogle Scholar
  82. Virkkunen, M., Nuutila, A., Goodwin, F.K., & Linnoila, M. (1987). Cerebrospinal fluid monoamine metabolite levels in male arsonists. Archives of General Psychiatry 44, 241–247.PubMedGoogle Scholar
  83. Wise, R. (1988). The neurobiology of craving: Implications for the understanding and treatment of addiction. Journal of Abnormal Psychology 97, 118–132.PubMedCrossRefGoogle Scholar
  84. Yoshimoto, K., McBride, W.J., Lument, L., & Li, T.K. (1992). Ethanol enhances the release of dopamine and serotonin in the nucleus accumbens of HAD and LAD lines of rats Alcoholism: Clinical and Experimental Research 16, 781–785.Google Scholar

Copyright information

© Kluwer Academic Publishers 2002

Authors and Affiliations

  • Helen M. Pettinati
    • 1
  • Henry R. Kranzler
    • 2
  • Julie Madaras
    • 1
  1. 1.Center for the Study of Addictions, Department of PsychiatryUniversity of Pennsylvania School of MedicinePhiladelphia
  2. 2.Alcohol Research Center, Department of PsychiatryUniversity of Connecticut School of MedicinFarmington

Personalised recommendations